verapamil has been researched along with Cancer of Prostate in 22 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required." | 1.43 | Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety. ( Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD, 2016) |
| "In human prostate cancer PC3 cells, the effect of Y-24180, a presumed specific platelet activation factor (PAF) receptor antagonist, on intracellular Ca2+ concentration ([Ca2+]i) was measured by using fura-2 as a Ca2+-sensitive fluorescent probe." | 1.32 | Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells. ( Chao, YY; Jan, CR, 2004) |
| "We conclude that VRACs in human prostate cancer epithelial cells are modulated via protein tyrosine phosphorylation." | 1.31 | Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line. ( Kostyuk, PG; Lemonnier, L; Mauroy, B; Prevarskaya, N; Shuba, YM; Skryma, R; Van Coppenolle, F, 2000) |
| "The treatment of advanced metastatic prostate cancer by hormone manipulation or orchiectomy is frequently followed by the appearance of hormone-insensitive and highly chemoresistant tumor cells." | 1.29 | Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. ( Baumgartner, G; Hamilton, G; Schirmböck, M; Sherwood, ER; Thalhammer, T; Theyer, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 5 (22.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colabufo, NA | 1 |
| Abate, C | 1 |
| Contino, M | 1 |
| Inglese, C | 1 |
| Niso, M | 1 |
| Berardi, F | 1 |
| Perrone, R | 1 |
| Wlodarczyk, N | 1 |
| Le Broc-Ryckewaert, D | 1 |
| Gilleron, P | 1 |
| Lemoine, A | 1 |
| Farce, A | 1 |
| Chavatte, P | 1 |
| Dubois, J | 1 |
| Pommery, N | 1 |
| Hénichart, JP | 1 |
| Furman, C | 1 |
| Millet, R | 1 |
| Chen, J | 1 |
| Ahn, S | 1 |
| Wang, J | 1 |
| Lu, Y | 1 |
| Dalton, JT | 1 |
| Miller, DD | 2 |
| Li, W | 2 |
| Bassetto, M | 2 |
| Ferla, S | 2 |
| Pertusati, F | 2 |
| Kandil, S | 2 |
| Westwell, AD | 2 |
| Brancale, A | 2 |
| McGuigan, C | 2 |
| Wang, Q | 1 |
| Arnst, KE | 1 |
| Wang, Y | 1 |
| Kumar, G | 1 |
| Ma, D | 1 |
| Chen, H | 1 |
| Wu, Z | 1 |
| Yang, J | 1 |
| White, SW | 1 |
| Sauvant, C | 1 |
| Thews, O | 2 |
| Wirth, C | 1 |
| Gekle, M | 2 |
| Fraser, SP | 2 |
| Grimes, JA | 2 |
| Diss, JK | 1 |
| Stewart, D | 1 |
| Dolly, JO | 1 |
| Djamgoz, MB | 2 |
| Fedoruk, MN | 1 |
| Giménez-Bonafé, P | 1 |
| Guns, ES | 1 |
| Mayer, LD | 1 |
| Nelson, CC | 1 |
| Jan, CR | 1 |
| Chao, YY | 1 |
| Gassner, B | 1 |
| Kelleher, DK | 1 |
| Theyer, G | 1 |
| Schirmböck, M | 1 |
| Thalhammer, T | 1 |
| Sherwood, ER | 1 |
| Baumgartner, G | 1 |
| Hamilton, G | 1 |
| Siegsmund, MJ | 1 |
| Kreukler, C | 1 |
| Steidler, A | 1 |
| Nebe, T | 1 |
| Köhrmann, KU | 1 |
| Alken, P | 1 |
| Wartenberg, M | 1 |
| Frey, C | 1 |
| Diedershagen, H | 1 |
| Ritgen, J | 1 |
| Hescheler, J | 1 |
| Sauer, H | 1 |
| Shuba, YM | 1 |
| Prevarskaya, N | 2 |
| Lemonnier, L | 2 |
| Van Coppenolle, F | 2 |
| Kostyuk, PG | 1 |
| Mauroy, B | 1 |
| Skryma, R | 2 |
| Chien, J | 1 |
| Shah, GV | 1 |
| Wong, BK | 1 |
| DeFeo-Jones, D | 1 |
| Jones, RE | 1 |
| Garsky, VM | 1 |
| Feng, DM | 1 |
| Oliff, A | 1 |
| Chiba, M | 1 |
| Ellis, JD | 1 |
| Lin, JH | 1 |
| Rybalchenko, V | 1 |
| Legrand, G | 1 |
| Le Bourhis, X | 1 |
| Batra, S | 1 |
| Popper, LD | 1 |
| Hartley-Asp, B | 1 |
| Steinsapir, J | 1 |
| Socci, R | 1 |
| Reinach, P | 1 |
| Kaneski, CR | 1 |
| Constantopoulos, G | 1 |
| Brady, RO | 1 |
22 other studies available for verapamil and Cancer of Prostate
| Article | Year |
|---|---|
PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma.
Topics: Adenocarcinoma; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; | 2008 |
Potent farnesyltransferase inhibitors with 1,4-diazepane scaffolds as novel destabilizing microtubule agents in hormone-resistant prostate cancer.
Topics: Androgen Antagonists; Azepines; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screeni | 2011 |
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dr | 2012 |
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Che | 2016 |
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug | 2016 |
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Topics: Animals; Cell Proliferation; Chalcones; Humans; Male; Melanoma; Mice; Mice, Nude; Models, Molecular; | 2018 |
Direct determination of intracellular daunorubicin in intact confluent monolayers of AT1 prostate carcinoma cells using a multiwell-multilabel counter.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Extracts; Cell Line, Tumor; C | 2008 |
Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation.
Topics: 4-Aminopyridine; Animals; Blotting, Western; Calcium Channel Blockers; Cell Line, Tumor; Charybdotox | 2003 |
P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; ATP Binding Cassette Transporter, Subfamily B, Mem | 2004 |
Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells.
Topics: Adenosine Triphosphate; Azepines; Calcium; Calcium Signaling; Cell Proliferation; Dihydropyridines; | 2004 |
Activity of drug efflux transporters in tumor cells under hypoxic conditions.
Topics: Acidosis; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Ca | 2008 |
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transpo | 1993 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Age | 1997 |
Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Chloride Channels; Doxorubic | 1998 |
Effects of voltage-gated ion channel modulators on rat prostatic cancer cell proliferation: comparison of strongly and weakly metastatic cell lines.
Topics: 4-Aminopyridine; Animals; Calcium Channel Blockers; Cell Division; Charybdotoxin; Dose-Response Rela | 2000 |
Volume-regulated chloride conductance in the LNCaP human prostate cancer cell line.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; 8-Bromo Cyclic Adenosine Monophosphate; Adenosine | 2000 |
Role of stimulatory guanine nucleotide binding protein (GSalpha) in proliferation of PC-3M prostate cancer cells.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenylyl Cyclases; Blotting, Western; Calcitonin; Calcium Ch | 2001 |
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
Topics: Animals; Antineoplastic Agents; Biotransformation; Doxorubicin; Drug Delivery Systems; Humans; Liver | 2001 |
Verapamil inhibits proliferation of LNCaP human prostate cancer cells influencing K+ channel gating.
Topics: Antineoplastic Agents; Binding Sites; Binding, Competitive; Calcium Channel Blockers; Cell Division; | 2001 |
Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells.
Topics: Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Radioisotopes; Calmodulin; Cell Divisio | 1991 |
Effects of androgen on intracellular calcium of LNCaP cells.
Topics: Calcium; Cell Line; Dihydrotestosterone; Fura-2; Humans; Kinetics; Male; Nandrolone; Prostatic Neopl | 1991 |
Effect of dimethylsulfoxide on the proliferation and glycosaminoglycan synthesis of rat prostate adenocarcinoma cells (PAIII) in vitro: isolation and characterization of DMSO-resistant cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Dimethyl Sulfoxide; Drug Resistance; | 1991 |